A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Study Title
- A Phase 1b, Open-Label Trial to Assess Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Teva Identifier
- TV53408-IMM-10209
ClinicalTrials.gov Identifier
- NCT06625177
Study Status
- Recruiting
Trial Condition(s)
- Vitiligo
Interventions
- Drug: TEV-53408
Study Description
- The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. Another primary objective is to evaluate the efficacy of TEV-53408. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years to 75 Years
Trial Duration
- November 15, 2024 - June 21, 2027
Phase
- Phase 1
Study Type
Interventional
